Publications
Detailed Information
Ongoing debates in the assessment of the HER2 status in breast cancer: A comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, Hyoungsuk | - |
dc.contributor.author | Seol, Hyesil | - |
dc.contributor.author | Kim, Wook Youn | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Park, In Ae | - |
dc.date.accessioned | 2009-05-19T22:49:12Z | - |
dc.date.available | 2009-05-19T22:49:12Z | - |
dc.date.issued | 2008-10-22 | - |
dc.identifier.citation | Bas Appl Pathol 2008; 1: 182-188 | en |
dc.identifier.issn | 1755-9294 | - |
dc.identifier.uri | https://hdl.handle.net/10371/3507 | - |
dc.description | The definitive version is available at www.blackwell-synergy.com. | en |
dc.description.abstract | Background and aims: HER2 status should be precisely evaluated in breast cancer to ensure appropriate patient management. Method: We evaluated HER2 status in 755 breast cancers including 92 consecutively resected cases by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Results: For the 92 consecutive cases, the positive rate of HER2 IHC (2+ and 3+) was 25.0%, and HER2 amplification (HER2/CEP17 ratio 2265 2.0) was observed in 21.7%. Of the 755 cases, 88% of IHC 3+ cases; 57% of IHC 2+ cases; 15% of IHC 1+ cases; and 1% of IHC 0 cases showed HER2 amplification. Notably, 20 (2.6%) of the 755 cases exhibited a HER2/CEP17 ratio between 1.8 and 2.2, which was recently classified equivocal by the ASCO/CAP. Most of them revealed HER2 high polysomy with an average copy number per cell between 3.29 and 7.24. Immunohistochemically, 4 of the 20 cases were luminal A, 12 were luminal B, and 3 were HER2 subtype. Conclusions: The relatively high rate of HER2 amplification among IHC 1+ or 2+ cases at our institute emphasizes the importance of validating HER2 testing in different laboratories and the need for complementary HER2 FISH in IHC 1+ patients. Most patients equivocal for HER2 amplification had HER2 high polysomy and expressed hormone receptor. | en |
dc.language.iso | en | en |
dc.publisher | Blackwell Publishing | en |
dc.subject | ASCO/CAP | en |
dc.subject | breast carcinoma | en |
dc.subject | FISH | en |
dc.subject | HER2 | en |
dc.subject | immunohistochemistry | en |
dc.title | Ongoing debates in the assessment of the HER2 status in breast cancer: A comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 고형석 | - |
dc.contributor.AlternativeAuthor | 설혜실 | - |
dc.contributor.AlternativeAuthor | 김욱연 | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.contributor.AlternativeAuthor | 한원식 | - |
dc.contributor.AlternativeAuthor | 노동영 | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 박인애 | - |
dc.identifier.doi | 10.1111/j.1755-9294.2008.00040.x | - |
dc.citation.journaltitle | Basic and Applied Pathology | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.